Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 59 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M365TGZ2dmO2aX;uJGF{e2G7 NIPEO44xNjgQvF2= NHvve|MzPGh? Mnnn[ZRp[W6xbB?= M2rwSIVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V? NGeyOpozPTd6N{C3PS=>
TE13 NHfvbHVHfW6ldHnvckBCe3OjeR?= MXiwMlPPxE1? Ml7YNlRp MlT0eZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= M3L1WFI2PTd7Nk[1
TE13 MonmRZBweHSxc3nzJGF{e2G7 MYSwMlPPxE1? MYGyOIg> M2iyeYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MoraNlU2Pzl4NkW=
MEFs MWDGeY5kfGmxbjDBd5NigQ>? M4DtR|XPxE1? M{Th[VE3cA>? M{\RZolv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? NGD4eWszPTR6Mk[zOC=>
SW480  MYXGeY5kfGmxbjDBd5NigQ>? NETa[o4xNjIQvF2= MVG0PIg> MlvMSG1UVw>? MVPy[ZZmenOnczDFUXQ> NEm0XIUzPTR|NEm5Oy=>
PC3  MW\GeY5kfGmxbjDBd5NigQ>? NIexe5QxNjIQvF2= MoXTOFhp M1LicWROW09? NYP4N5c4emW4ZYLz[ZMhTU2W NVvxNZRQOjV2M{S5PVc>
SW480  M3fDb2Z2dmO2aX;uJGF{e2G7 NVrPSWlXOC5zzszN MVy0PIg> M4n4b2ROW09? MnTOZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M4LEW|I2PDN2OUm3
PC3  MYnGeY5kfGmxbjDBd5NigQ>? MmPWNE4y|ryP M{DGTVQ5cA>? MVXEUXNQ MWXheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? M3;EZlI2PDN2OUm3
SW480  NET6T4dHfW6ldHnvckBCe3OjeR?= MVSwMlHPxE1? MVK0PIg> MW\EUXNQ NHLTSZFqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ M2fscVI2PDN2OUm3
PC3  MlT4SpVv[3Srb36gRZN{[Xl? NUe1RYY{OC5zzszN MlvPOFhp NXy0SY5PTE2VTx?= NYjmXHg2cW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NHW4TlIzPTR|NEm5Oy=>
A431 NFzpNotCeG:ydH;zbZMhSXO|YYm= MljjNk8yOC93MD:xNFBvVQ>? MYO0PIg> Ml;3SG1UVw>? MXLpcohq[mm2czD0bIUh[2WubDDndo94fGh? MkjVNlU{PzFyNkm=
A431 MVjGeY5kfGmxbjDBd5NigQ>? NYXmSIRCPTCwTR?= MkfENk83NzF{L{K0bC=> MVXEUXNQ NVfWcJBs[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NH72NFEzPTN5MUC2PS=>
MDA-MB-231 M3jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECxR3QxNTZyMH7N MlvHNlRp NWLlV21JTE2VTx?= MVXJR|UxKG:oIEGwNI5O MlLyNlUyQTJ5MkG=
MCF7 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSwMVYxOG6P NWDvVVdmOjSq M{jDfmROW09? MkHZTWM2OCCxZjC3OY5O M4ixPFI2OTl{N{Kx
SKOV-3 NYXodHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexMVEx|ryP NXrlcm0zOjSq NVHtSXJZTE2VTx?= M1HLbmlEPTBib3[gOU43|ryP NFzhO|UzPTF4OUS5NS=>
A549 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITMNVEyNTFyzszN M{XSPVI1cA>? MknSSG1UVw>? M1PpOmlEPTBib3[gN{4z|ryP NEDtTIEzPTF4OUS5NS=>
SKOV-3 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmwfHV7OC5zLUJOwG0> NY\MSXZyPDiq NHzsXVZFVVOR MUPJR|UxKG:oIECuO:69VQ>? NYHOdpdXOjVzNkm0PVE>
A549 NUD3Z5I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHRe2wxNjFvMd88US=> NFywZ3Q1QGh? NIDnXllFVVOR NFuwdXRKSzVyIH;mJFAvOjkQvF2= MV[yOVE3QTR7MR?=
SKOV-3 NX\Mbpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDhNE4xOS1yLkpOwG0> NUC2UZpJPzKq NGO4O4RFVVOR MU\JR|UxKG:oIECuN|LPxE1? NX7COpBrOjVzNkm0PVE>
A549 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWwMlAyNTBwOd88US=> NWLNTVdZPzKq M3PyfmROW09? MUPJR|UxKG:oIECuNFbPxE1? MVOyOVE3QTR7MR?=
HeLa NXPjSnR2TnWwY4Tpc44hSXO|YYm= MlXPNlUxdk1? MmDmNVZp MVHEUXNQ Mn6xbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= NUX5dmZKOjVzMU[2PFg>
CNE2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNFAuPjBybl2= NUnz[GxiOjRxNEivO|Jp NH21e3dqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVGyOFk3QTlyMR?=
PC3 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MortNVAxNTFyMEDuUS=> MUKyOIg> MUDJR|UxKG:oIEOwNI5O M1r4SlI1QDV2NkW4
LNCaP NX64bHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G3TlExOC1zMECwcm0> M4S3fVI1cA>? NFvnSHZKSzVyIH;mJFMxOG6P M2f0XlI1QDV2NkW4
HeLa  NWXOPGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\sNu69VQ>? NHPHWXc1QGh? NF;Bc5Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl MUiyOFg1PjF|NR?=
HMEC-1  NX\SdYtYTnWwY4Tpc44hSXO|YYm= NIC5VZI{ODCwTR?= M4nFNlI1cA>? NV3nUYZicW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? MWWyOFcyODZ|MR?=
HeLa NI\TNYlHfW6ldHnvckBCe3OjeR?= NETjUZMydU1? NH7RbIgxNjWq M1jM[IFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= NYTDZ5dVOjR5MEe0O|Q>
ACP02 NH;FSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5TYlqOjVyL{O1NE82ODCwTR?= NYfkSIZxOjSq NH\BNoZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P Mo\vNlQ3Pjh3NEe=
ACP03 M1j0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrhNIszPTBxM{WwM|UxOG6P NW\FWWJuOjSq Mmrn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NEXkN4YzPDZ4OEW0Oy=>
U87 GBM M2j2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAwOzByL{WwNEBvVQ>? MU[3NkBp M3z1XFExOCViZYToZY5wdA>? NFOyRpdz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> MnPGNlQ1PjR6NEG=
U87 GBM MXnGeY5kfGmxbjDBd5NigQ>? NWXWd|RSOTByL{WwNEBPdQ>? NYfk[JBZPDhiaB?= NVLoVYlHOTByJTDleIhidm:u Mn6zTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 MWCyOFQ3PDh2MR?=
RPE MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn4Ro4xNjJxMD60M|AvQC9zIN88US=> NVixSXVFOjRxNEivO|IhcA>? NHT4eFBFVVOR M3zoR4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 NU\Kb4FLOjR2NU[2NFI>
HT29  NHHVUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDE[mFqOThyIH7N MkDOO|IhcA>? MWjJR|UxKG:oIEG4NEBvVQ>? MnHCNlQ{Pjh{NkW=
hMSCs M{j6SGZ2dmO2aX;uJGF{e2G7 NEjtXmQ3NjJ3IH7N MkOxNlQhcA>? NX7kNpJKTE2VTx?= NFnKTmZ{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz M1PtZlI1OzF{M{W2
Huh7  M1jyb2Z2dmO2aX;uJGF{e2G7 MVqwMlEwOC53L{GuNEDPxE1? NFn6fIYzPGh? M2naRZN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NGrHbHgzPDJ4OU[3Ni=>
SKOV3 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kd2kxNjB3LUKg{txO NGrvdYIyOC9{ND:0PEBp NH\WSXJFVVOR M3jSc41m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NY\mTHViOjR{MkO4NFE>
A2780 M37YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCxUHMxNjB3LUKg{txO NXTVPZQ4OTBxMkSvOFghcA>? M{DVXWROW09? M13h[o1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NV2wZ3RVOjR{MkO4NFE>
SRA01/04  M124UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW4NE4zKM7:TR?= MYC0PEBp M{juNGROW09? M3XnO5N2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ M3TTR|I1OTV5OEe4
HLEB3 M{\tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DCWlAvOiEQvF2= NYfmemN5PDhiaB?= NWXFT4RYTE2VTx?= M1fjXpN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MkTQNlQyPTd6N{i=
SRA01/04  M4j3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHvNE41NzBwODFOwG0> NY\BS5F2PDhiaB?= NVrHfWZjTE2VTx?= NVH4WpJOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MU[yOFE2Pzh5OB?=
HLEB3 M2Gxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;YNE41NzBwODFOwG0> M{nxeFQ5KGh? Mn7uSG1UVw>? NFnvbXBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MofRNlQyPTd6N{i=
HCT116 M3XU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlIh|ryP MXyxNkBp M{\IeYVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u M1;VR|I1OTJ{MkOx
CA46 NGDjR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3PXXVJOy94L{GyM|I1NzR6IH7N MUO0PEBp MXvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh MnnBNlQxPjR7NUG=
PMNs MnqzSpVv[3Srb36gRZN{[Xl? M1Tsb|MxKG6P MnTiOFghcA>? NHHMNnVqdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> MVOyN|k5QDZzNx?=
H1299 NXHhVY8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjKSGl7OcLizszNxsA> M2XIUlI1NzR6L{eyJIg> NXjNeVVQ\XSqYX7vcC=> MVXpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> Mn:0NlM6OTZ4MEm=
A549 M1vjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHTNE4zPS9yLkWvNUDPxE1? NXvOVW9qOjRxNEivO|IhcA>? NGj6cIxmfGijbn;s NIHmZlhqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M{LWPFI{QDZ5OUmx
H1299 NEfPS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqyNE4zPS9yLkWvNUDPxE1? NH3CVpEzPC92OD:3NkBp NUK4R4R5\XSqYX7vcC=> NWW3OodXcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnLVNlM5Pjd7OUG=
A549 NUHS[ZFNSXCxcITvd4l{KEG|c3H5 NXPjRXE2OC53L{Gg{txO MXy0PEBp NIC3UJRmfGijbn;s NEL1R4FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MorHNlM5Pjd7OUG=
H1299 M3y1emFxd3C2b4Ppd{BCe3OjeR?= NFrFWnIxNjVxMTFOwG0> MYm0PEBp NWLyNlVw\XSqYX7vcC=> NXXTZodZcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVfDSWl3OjN6Nke5PVE>
SUM149PT NVjwPI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;iNk84NjVxMUCg{txO MoPaOFghcA>? NYHSSZc6TE2VTx?= NHXuNItqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= M1X2OlI{Pzl{NkO4
SUM190PT M1jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXe1NE8yODBxMkWwJI5O M4TvWlQ5KGh? MlLSSG1UVw>? MXfpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> MkTDNlM4QTJ4M{i=
HCT1 NFTacW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X6TVAvOi9zLkCvOU4xKM7:TR?= NF\ZWIYyOi9{ND:zOk81QCCq MVfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MmXGNlM4PzByMEC=
Lovo MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HIS|AvOi9zLkCvOU4xKM7:TR?= NGizWWwyOi9{ND:zOk81QCCq MUXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NV\PSZF3OjN5N{CwNFA>
AGS NY[5TJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HodlAvODF3LUGg{txO MorNO|IhcA>? M{LBRYlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MXyyN|c1PTB{NB?=
Huh7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HCNFEh|ryP M2TRXFI1KGh? NWryVWVkTE2VTx?= MkHDdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NVXzdoZwOjN4NEO5N|M>
ECC1 MVvGeY5kfGmxbjDBd5NigQ>? MXS1NFAhdk1? MoHJOUBl MVTEUXNQ MlfsbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NIXpdWYzOzV|MEe2PS=>
HEC1A M3n2PGZ2dmO2aX;uJGF{e2G7 NVnw[mtFPTByIH7N NH63doU2KGR? MmOxSG1UVw>? M2jpS4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NH:zd4QzOzV|MEe2PS=>
EN1 NYi1O|gzTnWwY4Tpc44hSXO|YYm= Mmn6OVAxKG6P NF;HSlM2KGR? MlH6SG1UVw>? MUTpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MYqyN|U{ODd4OR?=
MFE296 MkHESpVv[3Srb36gRZN{[Xl? MUe1NFAhdk1? NVf1[mhiPSCm MWjEUXNQ NGXlcJBqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MWqyN|U{ODd4OR?=
HASMCs MkKxSpVv[3Srb36gRZN{[Xl? MXuwMVUxOCCwTR?= MnXLOkBl M2frUoRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 MVSyN|UyQDR4Nx?=
U373 NEH4NopHfW6ldHnvckBCe3OjeR?= NXXEWmtKOC5{NT:wMlUwOSEQvF2= MlziNlQhcA>? NXzSWYgycW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= NWXSNG5OOjN2N{SxO|E>
ARN8  Mn7zSpVv[3Srb36gRZN{[Xl? MmXPNE4xPS1{IN88US=> NYe3VotpOjRiaB?= MVry[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> Mo[2NlM1PzB3NEC=
MCF7 NF2xfnRHfW6ldHnvckBCe3OjeR?= M1PZT|AvODVvMjFOwG0> NEf1OY8zPCCq NHvIZ3Bz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? Ml:3NlM1PzB3NEC=
H1299  MmLrSpVv[3Srb36gRZN{[Xl? NGqzcpUxNjN|4pETNeKhyrWP NYr0NYFzOjRxNEigbC=> NUTPSoxCTE2VTx?= M{DLVIlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NIP3cJUzOzR4MUm3OS=>
H1299 MkXKSpVv[3Srb36gRZN{[Xl? MWmwMlUh|ryP MmfFOFghcA>? M3K0VmROW09? M{e2ZYlvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> M4Lw[FI{PDZzOUe1
H1299 M3\xZ2Z2dmO2aX;uJGF{e2G7 MYqwMlUh|ryP M4\LWlQ5KGh? MWjEUXNQ NH7TPIZqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= MVmyN|Q3OTl5NR?=
MG-63  NHT2T2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHUOVIzOC5|IN88US=> NGntXoQyOi17NjDo MlPUSG1UVw>? NGDIVXVqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NYXHT2h2OjN2NUG4NVc>
LM8 M{nEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GzXFAvOyEQvF2= NHrkXYQyOi17NjDo NGLncWlFVVOR M3TBSIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= MV6yN|Q2OThzNx?=
K562 M{fHXWZ2dmO2aX;uJGF{e2G7 MXqwMlUh|ryP NUjaRYtsOjRiaB?= NVPoXGhX\XSqYX7vcC=> MkHY[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> NGqw[2wzOzR|MEm1Oy=>
HEL M1rWNGZ2dmO2aX;uJGF{e2G7 M4rI[VAvPSEQvF2= MV2yOEBp NVG5RpBb\XSqYX7vcC=> MkDC[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> NFSzN3czOzR|MEm1Oy=>
HL60 NV7lepR2SXCxcITvd4l{KEG|c3H5 MmC5NUDPxE1? NELOdlYzPCCq M3y4fYlv\HWlZYRCpINmdGxiZHXheIg> MnLwNlM1ODB3MUm=
KG1 MUXBdI9xfG:|aYOgRZN{[Xl? NXS2To1nOSEQvF2= NH\jPIUzPCCq M2n2[Ilv\HWlZYRCpINmdGxiZHXheIg> MXmyN|QxODVzOR?=
Kazumi M2XLVWFxd3C2b4Ppd{BCe3OjeR?= NEXUOVgyKM7:TR?= MUOyOEBp MVnpcoR2[2W|wrDj[YxtKGSnYYTo NH;MTWUzOzRyMEWxPS=>
K562 MnjxRZBweHSxc3nzJGF{e2G7 NUftdFM3OSEQvF2= NUnEOnZVOjRiaB?= MYLpcoR2[2W|wrDj[YxtKGSnYYTo MnvDNlM1ODB3MUm=
THP1 MXjBdI9xfG:|aYOgRZN{[Xl? NX[zZ5ZTOSEQvF2= NXmyVXRCOjRiaB?= MVzpcoR2[2W|wrDj[YxtKGSnYYTo M4XPW|I{PDByNUG5
SH-SY5Y M13oUWZ2dmO2aX;uJGF{e2G7 NFHpcXkzPTBibl2= MkLMNVYhcA>? M4\kR4Np[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= NFHIbYYzOzN{NkSyNi=>
HEK293 NWr0UHdVTnWwY4Tpc44hSXO|YYm= MknnNUDDvU4EoB?= MV6xPEBpyqB? MV;pcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ MmHxNlMzQDR6NEi=
HTK NFzJR|NHfW6ldHnvckBCe3OjeR?= NVy2[JRUPDByIH7N M{mxbFczKGh? NYPlVYdscW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? Mo\0NlMzQDRyMEK=
HTK MU\GeY5kfGmxbjDBd5NigQ>? NGjUXWIyODBvOECwcm0> NHf5S2Y4OiCq MU\icI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? NFrocmYzOzJ6NECwNi=>
Caco-2  MYjGeY5kfGmxbjDBd5NigQ>? M3rne|EhyrWPwrC= NYCxNnQ4OjRiaB?= M1SydoRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MoXtNlMyQTVyN{C=
HeLa NVzxdIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYexNFAhdk1? NF2wNpozPCCq Mk\OSG1UVw>? MWHJR|UxKG:oIEGwNI5O NGSzbo8zOzF4NUe0PC=>
HeLa MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4b|k1OCCwTR?= MlvIOFghcA>? NF;hdY9FVVOR NX3JWHZ5UUN3MDDv[kA1OG6P NYLyU5ZVOjNzNkW3OFg>
HeLa MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvjXWtjOjBibl2= NHTBRok4OiCq M3S0PGROW09? NFO0fHZKSzVyIH;mJFIxdk1? NHHuO|gzOzF4NUe0PC=>
HeLa MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PiZVExNzNyL{WwJI5O MnntO|IhcA>? MX\EUXNQ NYfUTJNMcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NGjzZ4szOzF4NUe0PC=>
MDA-MB-231 NHP4T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjuVI8zPS12MECgcm0> NYTDboNLPDhiaB?= MVPJR|UxKG:oIEK2N{4zdk4EoB?= NUHFV4ZkOjNyNUWxPVg>
MCF-7  MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvaNlUuPDByIH7N MmPqOFghcA>? MkToTWM2OCCxZjCyNlAvPG6P MojQNlMxPTVzOUi=
ECC-1  M13XVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwTpkyODBibl2= NHzxdHEzPCCq NF7KVJJmfGijbn;s MWHpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? NVHuSHNpOjNyMki4NFM>
HEC-1A MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74VFMyODBibl2= NIHC[2kzPCCq Mkiz[ZRp[W6xbB?= NEHoN3BqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= Ml\5NlMxOjh6MEO=
NHAC-kn NUj0WW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fI[lExNzFyMD:1NFAhdk1? MVSxNkBp M{OzSWROW09? NH;CTYRKSzVyIH;mJFUxOG6P MUmyN|AyPzh5MR?=
A549 NVzDXohjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKyOVAhdk1? NYXNTmNOPi15MjDo M{CwOWROW09? M4PUToNifXOnczDhJIdz\WG2ZYKgbY5pcWKrdH;yfUBm\m[nY4SgZ49u[mmwZTD3bZRpKFS[VDDvdkBmemyxdHnubYI> NWjZbJJnOjJ7OUS3PFA>
MG-63 M{Xsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS0NFI{ODBibl2= NWLiSJZxOTJiaB?= NWHIfIpNTE2VTx?= NUCwVGV7cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= MVSyNlc6QTN|OB?=
MG-63 M{Tn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTvN|AxKG6P M1r3RVI1KGh? NV70c|VHTE2VTx?= NHi2PYZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NGXRRWwzOjd7OUOzPC=>
MG-63 NFiwSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHXWopZOzByIH7N M3rPfFQ5KGh? MlK1SG1UVw>? NGLZO5ZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn MUCyNlc6QTN|OB?=
HL60  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LsW|E2OC1|NUCgcm0> NI\DSXQzPCCq Mn3ubY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MkfINlI4PTN5M{m=
U937 NF:4b3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:xZVE2OC1|NUCgcm0> M4HJd|I1KGh? Mo[xbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M1HlclIzPzV|N{O5
SCC-6 M17S[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjpWnB[OjByLUOyNFAhdk1? M1jGNVEzNzJ2L{S4JIg> NX2yS4N4TE2VTx?= MlO0bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2GySFIzPTV{M{Kx
U87  MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHmwWFYyODBvM{CwJI5o NFWxeIszPCCq NHXhN|BqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NH75S5UzOjJ5MEi0PS=>
K562 NUW2NlJQTnWwY4Tpc44hSXO|YYm= MW[xJO69VQ>? M1HHZlEzKGh? NHqwSlBFVVOR NYnp[IJt\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NUfvUVA4OjJzN{mxPVg>
Reh NXf1WXJSTnWwY4Tpc44hSXO|YYm= MYOwMlMwOSEQvF2= NHr0UZAyOiCq M2m0dGROW09? M2X5b4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NEXjbo8zOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID